Literature DB >> 22154245

Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis.

Eli Westerlund1, Peter Henriksson, Håkan Wallén, Outi Hovatta, Kenny Rodriguez Wallberg, Alexandra Antovic.   

Abstract

INTRODUCTION: Controlled ovarian hyperstimulation during in vitro fertilization (IVF) causes profound increments in serum estradiol which may influence haemostasis and the ovarian hyperstimulation syndrome. In the present study we investigated the effect of the standard IVF-stimulation protocol on coagulation and fibrinolysis as assessed by different global haemostatic assays.
MATERIALS AND METHODS: Blood samples were drawn from 31 women during the down-regulation phase when estradiol secretion is inhibited, and before egg retrieval, i.e. when estradiol levels are at supraphysiological levels, in the following called high level stimulation phase. Haemostasis was assessed during both treatment phases with 1) the calibrated automated thrombogram which measures thrombin generation, 2) overall haemostasis potential which measures fibrin formation and degradation and 3) fibrin gel permeability measurements which measures the quality of the fibrin network.
RESULTS: Estradiol increased from <150pg/mL to 5889pg/mL (range 1620-19500pg/mL). We found both increased thrombin generation as measured by the calibrated automated thrombogram (p<0.001) and an increase in overall haemostasis potential (p<0.001) from time of down-regulation to high level stimulation.
CONCLUSIONS: The assays used indicated procoagulable changes in haemostasis during in vitro fertilization. Further studies should evaluate their potential in the prediction of thrombosis and hyperstimulation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154245     DOI: 10.1016/j.thromres.2011.11.024

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  GnRH Antagonist Protocol Enhances Coagulation During Controlled Ovarian Stimulation for IVF.

Authors:  Magdalena Piróg; Olga Kacalska-Janssen; Robert Jach; Jakub Wyroba; Bartosz Chrostowski; Michał Ząbczyk; Joanna Natorska
Journal:  Reprod Sci       Date:  2022-07-12       Impact factor: 2.924

2.  Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study.

Authors:  Grigoris T Gerotziafas; Patrick Van Dreden; Emmanuelle Mathieu d'Argent; Eleftheria Lefkou; Matthieu Grusse; Marjorie Comtet; Rabiatou Sangare; Hela Ketatni; Annette K Larsen; Ismail Elalamy
Journal:  Thromb J       Date:  2017-03-28

3.  An enhanced clot growth rate before in vitro fertilization decreases the probability of pregnancy.

Authors:  A N Balandina; E M Koltsova; T A Teterina; A G Yakovenko; E U Simonenko; A V Poletaev; I V Zorina; A M Shibeko; T A Vuimo; S A Yakovenko; F I Ataullakhanov
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

4.  Relationship Between Estradiol and Hemostasis Determined Through Thromboelastography Profile in Controlled Ovarian Stimulation Cycles.

Authors:  Wiryawan Permadi; Mulyanusa Amarullah Ritonga; Hartanto Bayuaji; Niswan Helja; Corina Delarosa Khoirunnisa; Tono Djuwantono
Journal:  J Blood Med       Date:  2021-05-27

5.  Proteomics of Children Born After Intracytoplasmic Sperm Injection Reveal Indices of an Adverse Cardiometabolic Profile.

Authors:  Ioanna Kosteria; George Th Tsangaris; Alexandra Gkourogianni; Athanasios Anagnostopoulos; Aggeliki Papadopoulou; Ioannis Papassotiriou; Dimitrios Loutradis; George P Chrousos; Christina Kanaka-Gantenbein
Journal:  J Endocr Soc       Date:  2017-02-27

6.  Changes in the plasma microvesicle proteome during the ovarian hyperstimulation phase of assisted reproductive technology.

Authors:  Nina Olausson; Fariborz Mobarrez; Roman Zubarev; Alexey Chernobrovkin; Dorothea Rutishauser; Katarina Bremme; Eli Westerlund; Outi Hovatta; Håkan Wallén; Peter Henriksson
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.